BRCA1 and non-small cell lung carcinoma: However, we have identified a novel two-gene predictive model for platinum-treated advanced NSCLC, based on the mRNA expression of BRCA1 and 53BP1. The patients who benefited most from first-line platinum-based treatment were those expressing low levels of both BRCA1 and 53BP1, who attained an impressive median PFS of 10.3 months and OS of 19.3 months.